Department of Bioethics and Humanities, University of Washington, Seattle, Washington (W.B.).
The Hastings Center, Garrison, New York (E.P.).
Ann Intern Med. 2022 Jul;175(7):994-1000. doi: 10.7326/M21-4109. Epub 2022 Apr 19.
Genomic tests expand diagnostic and screening opportunities but also identify genetic variants of uncertain clinical significance (VUSs). Only a minority of VUSs are likely to prove pathogenic when later reassessed, but resolution of the uncertainty is rarely timely. That uncertainty adds complexity to clinical decision making and can result in harms and costs to patients and the health care system, including the time-consuming analysis required to interpret a VUS and the potential for unnecessary treatment and adverse psychological effects. Current efforts to improve variant interpretation will help reduce the scope of the problem, but the high prevalence of rare and novel variants in the human genome points to VUSs as an ongoing challenge. Additional strategies can help mitigate the potential harms of VUSs, including testing protocols that limit identification or reporting of VUSs, subclassification of VUSs according to the likelihood of pathogenicity, routine family-based evaluation of variants, and enhanced counseling efforts. All involve tradeoffs, and the appropriate balance of measures is likely to vary for different test uses and clinical settings. Cross-specialty deliberation and public input could contribute to systematic and broadly supported policies for managing VUSs.
基因组检测扩大了诊断和筛查的机会,但也发现了一些临床意义不确定的遗传变异(VUS)。只有少数 VUS 在后续重新评估时可能被证明具有致病性,但不确定性的解决很少是及时的。这种不确定性增加了临床决策的复杂性,并可能给患者和医疗保健系统带来危害和成本,包括解释 VUS 所需的耗时分析,以及潜在的不必要治疗和不良心理影响。目前,改善变异解释的努力将有助于减少问题的范围,但人类基因组中罕见和新型变异的高患病率表明 VUS 仍然是一个持续存在的挑战。其他策略可以帮助减轻 VUS 的潜在危害,包括限制识别或报告 VUS 的测试方案、根据致病性的可能性对 VUS 进行细分分类、对变体进行常规的基于家族的评估,以及加强咨询工作。所有这些都涉及权衡取舍,对于不同的测试用途和临床环境,适当的措施平衡可能会有所不同。跨专业的审议和公众的意见可以为管理 VUS 制定系统和广泛支持的政策做出贡献。